Patents-Review.com
ClassID:

109162 ⎘

C12N2310/315 - page 7 - CPC Classification

Classification description:

Structure or type of the nucleic acid; Chemical structure of the backbone Phosphorothioates

Recent Application in this class:
#1801
20200308579
2020-10-01

Liposomal spherical nucleic acid (SNA) constructs presenting antisense oligonucleotides (ASO) for specific knockdown of interleukin 17 receptor mRNA

 #1802
20200299730
2020-09-24

PRIMARY CELL GENE EDITING

 #1803
20200299698
2020-09-24

Xanthine dehydrogenase (XDH) IRNA compositions and methods of use thereof

 #1804
20200299692
2020-09-24

Oligonucleotide compositions and methods thereof

 #1805
20200299691
2020-09-24

RNAi agents for inhibiting expression of alpha-ENaC and methods of use

 #1806
20200299690
2020-09-24

RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)

 #1807
20200299689
2020-09-24

MODIFIED CPF1 GUIDE RNA

 #1808
20200297754
2020-09-24

Compositions and methods for inhibiting HMGB1 expression

 #1809
20200291407
2020-09-17

TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF

 #1810
20200291406
2020-09-17

PREVENTIVE OR THERAPEUTIC AGENT FOR FIBROSIS

 #1811
20200291405
2020-09-17

HEPATITIS D VIRUS (HDV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

 #1812
20200291399
2020-09-17

Oligonucleotide comprising an inosine for treating DMD

 #1813
20200291398
2020-09-17

Gapmers and methods of using the same for the treatment of muscular dystrophy

 #1814
20200283801
2020-09-10

Exosomal loading using hydrophobically modified oligonucleotides

 #1815
20200283776
2020-09-10

Splice Switching Oligomers for TNF Superfamily Receptors and Their Use in Treatment of Disease

 #1816
20200283775
2020-09-10

Methods and compositions for inhibiting expression of LDHA

 #1817
20200283772
2020-09-10

Antisense oligonucleotides for inducing exon skipping and methods of use thereof

 #1818
20200283766
2020-09-10

Compositions and Methods for Inhibiting Expression of Transthyretin

 #1819
20200283765
2020-09-10

Methods for Treatment of Alport Syndrome

 #1820
20200282074
2020-09-10

NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING

 #1821
20200277610
2020-09-03

Compositions and methods for inhibiting expression of RRM2 genes

 #1822
20200277604
2020-09-03

Modulators of MALAT1 expression

 #1823
20200277599
2020-09-03

Insulin-like growth factor binding protein, acid labile subunit (IGFALS) and insulin-like growth factor 1 (IGF-1) iRNA compositions and methods of use thereof

 #1824
20200276322
2020-09-03

Peptide compositions and methods of use thereof

 #1825
20200276224
2020-09-03

METHODS AND COMPOSITIONS FOR MODULATING APOLIPOPROTEIN (A) EXPRESSION

 #1826
20200276222
2020-09-03

2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS

 #1827
20200276221
2020-09-03

ANTISENSE COMPOUNDS

 #1828
20200270609
2020-08-27

Single-Stranded RNAI Oligonucleotides Targeting APOC-III

 #1829
20200270608
2020-08-27

Modulation of huntingtin expression

 #1830
20200270605
2020-08-27

Dynamic pharmacokinetic-modifying anchors

 #1831
20200268905
2020-08-27

RNA-modulating agents

 #1832
20200268898
2020-08-27

GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF

 #1833
20200268879
2020-08-27

Amphiphilic oligodeoxynucleotide conjugates as adjuvant enhancers

 #1834
20200263183
2020-08-20

Complement component iRNA compositions and methods of use thereof

 #1835
20200263179
2020-08-20

COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION OF LPA

 #1836
20200263176
2020-08-20

Compositions and Methods for Inhibition of Expression of Apolipoprotein C-III (APOC3) Genes

 #1837
20200255857
2020-08-13

CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING BETA HEMOGLOBINOPATHIES

 #1838
20200255837
2020-08-13

SPHERICAL NUCLEIC ACID TLR9 AGONISTS

 #1839
20200255836
2020-08-13

NUCLEIC ACID APTAMER FOR INHIBITING ACTIVITY OF GENOME-EDITING ENZYME

 #1840
20200255833
2020-08-13

Therapeutic compositions

 #1841
20200255827
2020-08-13

Stabilized HNF4A saRNA compositions and methods of use

 #1842
20200255826
2020-08-13

HNF4A saRNA compositions and methods of use

 #1843
20200248185
2020-08-06

Methods and compositions using RNA interference and antisense oligonucleotides for inhibition of KRAS

 #1844
20200248183
2020-08-06

TLR9-TARGETED SPHERICAL NUCLEIC ACIDS HAVING POTENT ANTITUMOR ACTIVITY

 #1845
20200247884
2020-08-06

Oligonucleotides for reduction of PD-L1 expression

 #1846
20200247882
2020-08-06

Agents that modulate TMEM230 as angiogenesis regulators and that detect TMEM230 as markers of metastasis

 #1847
20200239893
2020-07-30

Therapy

 #1848
20200239890
2020-07-30

Compositions and methods for inhibition of expression of protein C (PROC) genes

 #1849
20200239888
2020-07-30

Compositions and methods for modulation of protein aggregation

 #1850
20200239886
2020-07-30

Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-mRNA

 #1851
20200239883
2020-07-30

Compositions for modulating expression of C9ORF72 antisense transcript

 #1852
20200239882
2020-07-30

COMPOSITIONS FOR MODULATING C9ORF72 EXPRESSION

 #1853
20200239881
2020-07-30

Morpholino modified oligomeric compounds

 #1854
20200237802
2020-07-30

Oligonucleotides to treat eye disease

 #1855
20200231971
2020-07-23

Methods for treatment of polycystic kidney disease

 #1856
20200231969
2020-07-23

Reducing intron retention

 #1857
20200231967
2020-07-23

Double-stranded RNA molecule targeting CKIP-1 and use thereof

 #1858
20200231966
2020-07-23

Agents useful in treating facioscapulohumeral muscular dystrophy

 #1859
20200230168
2020-07-23

Nucleic acid oligomers and uses therefor

 #1860
20200224203
2020-07-16

ANTISENSE OLIGONUCLEOTIDE DIRECTED REMOVAL OF PROTEOLYTIC CLEAVAGE SITES, THE HCHWA-D MUTATION, AND TRINUCLEOTIDE REPEAT EXPANSIONS

 #1861
20200224202
2020-07-16

Immunosuppression-reverting oligonucleotides inhibiting the expression of CD39

 #1862
20200224201
2020-07-16

Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

 #1863
20200224198
2020-07-16

COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION

 #1864
20200216846
2020-07-09

Antisense Compounds and Uses Thereof

 #1865
20200216845
2020-07-09

ANTISENSE OLIGONUCLEOTIDES FOR MODULATING RELA EXPRESSION

 #1866
20200216844
2020-07-09

SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

 #1867
20200215113
2020-07-09

CHEMICALLY MODIFIED OLIGONUCLEOTIDES

 #1868
20200208158
2020-07-02

Products and compositions

 #1869
20200208154
2020-07-02

ALLELE SELECTIVE INHIBITION OF MUTANT C9ORF72 FOCI EXPRESSION BY DUPLEX RNAS TARGETING THE EXPANDED HEXANUCLEOTIDE REPEAT

 #1870
20200208152
2020-07-02

STABILIZED SARNA COMPOSITIONS AND METHODS OF USE

 #1871
20200208150
2020-07-02

METHODS FOR TREATING OR PREVENTING CONTACT-ACTIVATION PATHWAY-ASSOCIATED DISEASES USING iRNA COMPOSITIONS TARGETING FACTOR XII (HAGEMAN FACTOR) (F12)

 #1872
20200208149
2020-07-02

Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use

 #1873
20200208147
2020-07-02

Modulators of IRF5 expression

 #1874
20200208111
2020-07-02

GENOME-EDITED NK CELL AND METHODS OF MAKING AND USING

 #1875
20200199596
2020-06-25

RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (SINA)

 #1876
20200199595
2020-06-25

Allele-specific therapy for Huntington disease haplotypes

 #1877
20200199591
2020-06-25

Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof

 #1878
20200199590
2020-06-25

Antisense oligonucleotides for inducing exon skipping and methods of use thereof

 #1879
20200199589
2020-06-25

Compounds and methods for reducing Tau expression

 #1880
20200199586
2020-06-25

Targeted RNA editing

 #1881
20200197526
2020-06-25

REFILLABLE DRUG DELIVERY DEVICES AND METHODS OF USE THEREOF

 #1882
20200197525
2020-06-25

Modulators of PCSK9 expression

 #1883
20200197435
2020-06-25

Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes

 #1884
20200190523
2020-06-18

PKLR inhibition in the treatment of NAFLD and HCC

 #1885
20200190522
2020-06-18

COMPOUNDS AND METHODS FOR MODULATING TMPRSS6 EXPRESSION

 #1886
20200190520
2020-06-18

MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION

 #1887
20200190517
2020-06-18

Organic compositions to treat EPAS1-related diseases

 #1888
20200190515
2020-06-18

Oligonucleotide compositions and methods of use thereof

 #1889
20200190512
2020-06-18

Nucleic acid molecules and their use in therapy

 #1890
20200190511
2020-06-18

MICRO-RNA FAMILY THAT MODULATES FIBROSIS AND USES THEREOF

 #1891
20200181650
2020-06-11

Primary cell gene editing

 #1892
20200181622
2020-06-11

Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field

 #1893
20200181614
2020-06-11

COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE

 #1894
20200179435
2020-06-11

Modulators of FOXP3 expression

 #1895
20200172935
2020-06-04

Modified Cpf1 MRNA, modified guide RNA, and uses thereof

 #1896
20200172909
2020-06-04

Ketohexokinase (KHK) iRNA compositions and methods of use thereof

 #1897
20200172903
2020-06-04

ENA ANTISENSE OLIGONUCLEOTIDE FOR INHIBITION OF alpha-SYNUCLEIN EXPRESSION

 #1898
20200172902
2020-06-04

Compositions and methods for detecting and treating insulin resistance

 #1899
20200171069
2020-06-04

Methods for treating hepatitis B infection

 #1900
20200165634
2020-05-28

Primary cell gene editing

 #1901
20200165618
2020-05-28

Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders

 #1902
20200165606
2020-05-28

Modified Oligonucleotides for Treatment of Polycystic Kidney Disease

 #1903
20200164195
2020-05-28

Methods for cancer treatment

 #1904
20200164066
2020-05-28

Methods and compositions for inducing protective immunity

 #1905
20200157550
2020-05-21

RNAi inhibition of alpha-ENaC expression

 #1906
20200157548
2020-05-21

COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS

 #1907
20200157546
2020-05-21

ANTISENSE OLIGONUCLEOTIDES FOR MODULATING HTRA1 EXPRESSION

 #1908
20200157545
2020-05-21

Oligonucleotide compositions and methods of use thereof

 #1909
20200157537
2020-05-21

Modulating RNA Interactions with Polycomb Repressive Complex 1 (PRC1)

 #1910
20200157535
2020-05-21

METHODS AND COMPOSITIONS FOR MODULATING ALPHA-1-ANTITRYPSIN EXPRESSION

 #1911
20200149050
2020-05-14

Compositions and methods for inhibiting TIGIT gene expression

 #1912
20200149047
2020-05-14

MODULATORS OF COMPLEMENT FACTOR B

 #1913
20200149043
2020-05-14

RNA modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders

 #1914
20200149040
2020-05-14

Antisense nucleic acids

 #1915
20200147123
2020-05-14

Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection

 #1916
20200140871
2020-05-07

Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder

 #1917
20200140869
2020-05-07

Modulators of PNPLA3 expression

 #1918
20200140866
2020-05-07

Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

 #1919
20200140864
2020-05-07

Hepatitis B virus (HBV) iRNA compositions and methods of use thereof

 #1920
20200140859
2020-05-07

COMPOUNDS THAT TARGET MYC microRNA RESPONSIVE ELEMENTS FOR THE TREATMENT OF MYC-ASSOCIATED CANCER

 #1921
20200140857
2020-05-07

Methods and means for treating DNA repeat instability associated genetic disorders

 #1922
20200138847
2020-05-07

Myostatin iRNA compositions and methods of use thereof

 #1923
20200138846
2020-05-07

Enzymatic replacement therapy and antisense therapy for Pompe disease

 #1924
20200131517
2020-04-30

Treatment of Sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a Sirtuin (SIRT)

 #1925
20200131516
2020-04-30

Molecules and agents for treating hepatitis B virus

 #1926
20200123551
2020-04-23

Compositions and methods for modulating growth hormone receptor expression

 #1927
20200123548
2020-04-23

TREATMENT OF ANGIOGENESIS-ASSOCIATED DISEASES USING RNA COMPLEXES THAT TARGET ANGPT2 AND PDGFB

 #1928
20200123261
2020-04-23

NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF

 #1929
20200115711
2020-04-16

Modulation of angiopoietin-like 3 expression

 #1930
20200115710
2020-04-16

HETERO DOUBLE-STRANDED antimiR

 #1931
20200115411
2020-04-16

Antisense nucleic acids

 #1932
20200109405
2020-04-09

Treatment of atopic dermatitis and asthma using RNA complexes that target IL4Rα, TRPA1, or F2RL1

 #1933
20200109402
2020-04-09

Methods of reducing expression of x-inactivation escapee genes and autosomal genes

 #1934
20200109162
2020-04-09

Antisense nucleic acids

 #1935
20200102560
2020-04-02

POLYNUCLEOTIDE AGENTS TARGETING SERPINC1 (AT3) AND METHODS OF USE THEREOF

 #1936
20200102343
2020-04-02

Antisense nucleic acids

 #1937
20200095583
2020-03-26

Methods and compositions for managing vascular conditions

 #1938
20200095582
2020-03-26

BCL11A guide delivery

 #1939
20200095581
2020-03-26

MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPODYSTROPHY POPULATIONS

 #1940
20200087663
2020-03-19

O-methyl rich fully stabilized oligonucleotides

 #1941
20200087662
2020-03-19

Inhibition of poly(A) binding protein and the treatment of pain

 #1942
20200087661
2020-03-19

Compositions for modulating Ataxin 2 expression

 #1943
20200085942
2020-03-19

NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS IMMUNOSTIMULATING AGENT/ADJUVANT

 #1944
20200080088
2020-03-12

APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

 #1945
20200080085
2020-03-12

Serpina1 iRNA compositions and methods of use thereof

 #1946
20200080083
2020-03-12

OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF

 #1947
20200080080
2020-03-12

Therapeutic drug for Alport's syndrome

 #1948
20200071698
2020-03-05

Therapeutic agent for treating cancer comprising anti-miRNA-albumin composite

 #1949
20200071696
2020-03-05

Compositions of asymmetric interfering RNA and uses thereof

 #1950
20200069723
2020-03-05

COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

 #1951
20200069722
2020-03-05

Allele specific modulators of P23H rhodopsin

 #1952
20200069720
2020-03-05

MicroRNA (miRNA) and Downstream Targets for Diagnostic and Therapeutic Purposes

 #1953
20200063136
2020-02-27

Anti-connexin compounds targeted to connexins and methods of use thereof

 #1954
20200063134
2020-02-27

Oligonucleotide therapy for Leber Congenital Amaurosis

 #1955
20200063133
2020-02-27

Products and compositions

 #1956
20200063128
2020-02-27

Compositions of asymmetric interfering RNA and uses thereof

 #1957
20200057052
2020-02-20

Oligonucleotides for inducing paternal UBE3A expression

 #1958
20200056187
2020-02-20

SELECTIVE ANTISENSE COMPOUNDS AND USES THEREOF

 #1959
20200056185
2020-02-20

COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION

 #1960
20200056181
2020-02-20

Post-selex modification methods

 #1961
20200056179
2020-02-20

Compounds and methods for reducing ATXN2 expression

 #1962
20200056176
2020-02-20

MODULATION OF APOLIPOPROTEIN CIII (APOCIII) EXPRESSION

 #1963
20200056175
2020-02-20

COMPOSITIONS AND METHODS FOR INHIBITIION OF EXPRESSION OF PROTEIN C (PROC) GENES

 #1964
20200056173
2020-02-20

Oligonucleotide compositions and methods thereof

 #1965
20200056167
2020-02-20

Modified nucleic acids, hybrid guide RNAs, and uses thereof

 #1966
20200054679
2020-02-20

Compositions and methods for gene editing in T cells using CRISPR/Cpf1

 #1967
20200048638
2020-02-13

COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION

 #1968
20200048344
2020-02-13

Oligonucleotides for reduction of PD-L1 expression

 #1969
20200040343
2020-02-06

Compositions and methods for the treatment of hypercholesterolemia

 #1970
20200040342
2020-02-06

Compositions for modulating SOD-1 expression

 #1971
20200040341
2020-02-06

Modulators of diacyglycerol acyltransferase 2 (DGAT2)

 #1972
20200040333
2020-02-06

Compositions and methods for modulating SMN gene family expression

 #1973
20200032268
2020-01-30

Treatment of CNS injury with RNAi therapeutics

 #1974
20200032264
2020-01-30

METHODS FOR DOSING AND MONITORING SMAD7 ANTISENSE OLIGONUCLEOTIDE TREATMENT USING BIOMARKER LEVELS

 #1975
20200032260
2020-01-30

Compositions and methods for modulation of IKBKAP splicing

 #1976
20200032259
2020-01-30

Complement component C5 iRNA compositions and methods of use thereof

 #1977
20200032258
2020-01-30

COMPLEMENT COMPONENT C5 IRNA COMPOSITIONS AND METHODS OF USE THEREOF

 #1978
20200032257
2020-01-30

Methods for treating Alzheimer's disease

 #1979
20200030361
2020-01-30

OLIGONUCLEOTIDES CONTAINING 2'-DEOXY-2'FLUORO-BETA-D-ARABINOSE NUCLEIC ACID (2'-FANA) FOR TREATMENT AND DIAGNOSIS OF RETROVIRAL DISEASES

 #1980
20200024605
2020-01-23

Oligomers and oligomer conjugates

 #1981
20200024600
2020-01-23

Oligonucleotides for modulating ATXN2 expression

 #1982
20200017856
2020-01-16

Targeting human satellite II (HSATII)

 #1983
20200017854
2020-01-16

MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPOPROTEIN LIPASE DEFICIENT (LPLD) POPULATIONS

 #1984
20200010831
2020-01-09

Oligonucleotides for modulating Tau expression

 #1985
20200009181
2020-01-09

Antisense oligonucleotides for inhibition of PD-L1 expression and treating cancer

 #1986
20200002701
2020-01-02

Reduced size self-delivering RNAI compounds

 #1987
20200000839
2020-01-02

Modulation of Factor 11 expression

 #1988
20190390197
2019-12-26

OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF

 #1989
20190390195
2019-12-26

MODIFIED GUIDE RNAS, METHODS AND USES

 #1990
20190382797
2019-12-19

Methods and systems for guide RNA design and use

 #1991
20190382772
2019-12-19

Antisense oligonucleotides for use in treating Alzheimer's disease

 #1992
20190382762
2019-12-19

Chemically-modified siRNA

 #1993
20190382751
2019-12-19

MODIFIED CRISPR RNA AND USES THEREOF

 #1994
20190381089
2019-12-19

Oligonucleotides to treat eye disease

 #1995
20190381088
2019-12-19

Anti-IL-17 aptamer having improved retention in blood

 #1996
20190376091
2019-12-12

Primary cell gene editing

 #1997
20190376086
2019-12-12

Primary cell gene editing

 #1998
20190374472
2019-12-12

Antisense Compositions and Methods of Making and Using Same

 #1999
20190367925
2019-12-05

Treatment of idiopathic pulmonary fibrosis using RNA complexes that target connective tissue growth factor

 #2000
20190367923
2019-12-05

Antisense oligonucleotides that inhibit influenza virus replication and uses thereof

 #2001
20190367920
2019-12-05

ANTISENSE OLIGONUCLEOTIDES FOR MODULATING NFKB1 EXPRESSION

 #2002
20190367919
2019-12-05

Antisense oligonucleotides for the treatment of Stargardt disease

 #2003
20190367916
2019-12-05

Compositions for modulating C9ORF72 expression

 #2004
20190367914
2019-12-05

Conjugated antisense compounds and their use

 #2005
20190365795
2019-12-05

OLIGONUCLEOTIDES FOR MODULATING ATXN2 EXPRESSION

 #2006
20190359984
2019-11-28

Compositions and methods for inhibiting gene expression of factor XII

 #2007
20190359981
2019-11-28

Modulators of APOL1 expression

 #2008
20190359980
2019-11-28

OLIGONUCLEOTIDE COMPOSITIONS AND USES THEREOF

 #2009
20190359979
2019-11-28

Oligomeric compounds comprising α-β-constrained nucleic acid

 #2010
20190352645
2019-11-21

Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

 #2011
20190352641
2019-11-21

Oligonucleotide complexes for use in RNA editing

 #2012
20190350963
2019-11-21

Sterile formulation comprising a stable phosphorothioate oligonucleotide

 #2013
20190350962
2019-11-21

METHODS FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES USING TRANSTHYRETIN (TTR) iRNA COMPOSITIONS

 #2014
20190345498
2019-11-14

Modified iRNA agents

 #2015
20190345496
2019-11-14

ANTISENSE OLIGONUCLEOTIDES FOR MODULATING RELB EXPRESSION

 #2016
20190345495
2019-11-14

ANTISENSE OLIGONUCLEOTIDES FOR MODULATING NFKB2 EXPRESSION

 #2017
20190345492
2019-11-14

Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases

 #2018
20190345188
2019-11-14

Bicyclic nucleosides and oligomers prepared therefrom

 #2019
20190343863
2019-11-14

Modulation of Lnc05 expression

 #2020
20190338288
2019-11-07

MODULATION OF TMPRSS6 EXPRESSION

 #2021
20190338286
2019-11-07

ANTISENSE OLIGONUCLEOTIDES FOR MODULATING REL EXPRESSION

 #2022
20190338283
2019-11-07

METHODS AND COMPOSITIONS FOR TREATING A SUBJECT WITH A SMAD7 ANTISENSE OLIGONUCLEOTIDE

 #2023
20190338281
2019-11-07

SELECTIVE ANTISENSE COMPOUNDS AND USES THEREOF

 #2024
20190330639
2019-10-31

RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)

 #2025
20190330634
2019-10-31

Method for generating aptamers with improved off-rates

 #2026
20190330630
2019-10-31

Endosomal cleavable linkers

 #2027
20190330628
2019-10-31

Methods for intracellular delivery and enhanced gene targeting

 #2028
20190330626
2019-10-31

COMPOUNDS AND METHODS FOR USE IN DYSTROPHIN TRANSCRIPT

 #2029
20190323014
2019-10-24

Therapeutic inhibition of lactate dehydrogenase and agents therefor

 #2030
20190323013
2019-10-24

ANTISENSE OLIGONUCLEOTIDES DIRECTED AGAINST CONNECTIVE TISSUE GROWTH FACTOR AND USES THEREOF

 #2031
20190323010
2019-10-24

Antisense oligonucleotides for inducing exon skipping and methods of use thereof

 #2032
20190323009
2019-10-24

Piston arrangement

 #2033
20190323006
2019-10-24

COMPOUNDS AND METHODS FOR MODULATION OF SMN2

 #2034
20190321388
2019-10-24

Pharmaceutical compositions and methods for potentiating gene silencing

 #2035
20190321387
2019-10-24

COMPOUNDS AND METHODS FOR MODULATION OF TRANSCRIPT PROCESSING

 #2036
20190316138
2019-10-17

Oligonucleotide compositions with enhanced efficiency

 #2037
20190316137
2019-10-17

Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

 #2038
20190316127
2019-10-17

Serpina1 iRNA compositions and methods of use thereof

 #2039
20190316122
2019-10-17

Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof

 #2040
20190316121
2019-10-17

Modified guide RNAs

 #2041
20190315796
2019-10-17

Antisense nucleic acids

 #2042
20190310244
2019-10-10

Oligonucleotides for inducing paternal UBE3A expression

 #2043
20190309306
2019-10-10

RNAi constructs for inhibiting ASGR1 expression and methods of use thereof

 #2044
20190309304
2019-10-10

Antisense compounds targeting Leucine-Rich repeat kinase 2(LRRK2) for the treatment of Parkinsons disease

 #2045
20190309303
2019-10-10

Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene

 #2046
20190309302
2019-10-10

Antisense oligonucleotides

 #2047
20190309295
2019-10-10

Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene

 #2048
20190309293
2019-10-10

Compositions and Methods for Inhibiting Expression of Transthyretin

 #2049
20190309292
2019-10-10

Compounds and methods for enhanced cellular uptake

 #2050
20190309291
2019-10-10

CCCTC-binding factor (CTCF) RNA interactome

 #2051
20190309047
2019-10-10

Soluble TNF Receptors and Their Use in Treatment of Disease

 #2052
20190300879
2019-10-03

Methods for enhancing utrophin production via inhibition of microRNA

 #2053
20190300878
2019-10-03

METHODS AND MODIFICATIONS THAT PRODUCE ssRNAi COMPOUNDS WITH ENHANCED ACTIVITY, POTENCY AND DURATION OF EFFECT

 #2054
20190298847
2019-10-03

Compositions and methods of treating muscle atrophy and myotonic dystrophy

 #2055
20190292547
2019-09-26

RNAi agents for Hepatitis B virus infection

 #2056
20190292541
2019-09-26

METHOD FOR EFFICIENT EXON (44) SKIPPING IN DUCHENNE MUSCULAR DYSTROPHY AND ASSOCIATED MEANS

 #2057
20190292540
2019-09-26

SPINAL MUSCULAR ATROPHY (SMA) TREATMENT VIA TARGETING OF SMN2 SPLICE SITE INHIBITORY SEQUENCES

 #2058
20190284558
2019-09-19

Compositions and methods for inhibiting gene expression of alpha-1 AntiTrypsin

 #2059
20190284557
2019-09-19

DOSAGES AND METHODS FOR DELIVERING LIPID FORMULATED NUCLEIC ACID MOLECULES

 #2060
20190284554
2019-09-19

MicroRNAs and methods of their use

 #2061
20190284542
2019-09-19

Materials and methods for treatment of hemoglobinopathies

 #2062
20190282692
2019-09-19

SELECTIVE LOCAL INHIBITION OF TNFR1-MEDIATED FUNCTIONS AT THE SITE OF ANTIGEN/ALLERGEN PRESENTATION

 #2063
20190276832
2019-09-12

Compounds and methods for modulation of dystrophia myotonica-protein kinase (DMPK) expression

 #2064
20190276829
2019-09-12

Immunostimulatory sequence oligonucleotides and methods of using the same

 #2065
20190276823
2019-09-12

SELECTIVE ANTISENSE COMPOUNDS AND USES THEREOF

 #2066
20190275148
2019-09-12

CAMK2D antisense oligonucleotides and uses thereof

 #2067
20190273531
2019-09-05

FHSS hotspot device and methods

 #2068
20190270994
2019-09-05

Antisense molecules and methods for treating pathologies

 #2069
20190270993
2019-09-05

Therapeutic targeting of a microRNA to treat Duchenne muscular dystrophy

 #2070
20190270991
2019-09-05

Compositions for delivery of cargo to cells

 #2071
20190270990
2019-09-05

Antisense compounds and uses thereof

 #2072
20190269773
2019-09-05

Methods and compositions for adaptive immune modulation

 #2073
20190269728
2019-09-05

COMPOSITIONS FOR DELIVERY OF CARGO TO CELLS

 #2074
20190264211
2019-08-29

Modulation of gene expression and screening for deregulated protein expression

 #2075
20190264208
2019-08-29

Method for Generating Aptamers with Improved Off-Rates

 #2076
20190264207
2019-08-29

Therapeutic compositions

 #2077
20190264204
2019-08-29

Compositions for modulating C9ORF72 expression

 #2078
20190264203
2019-08-29

GLYCOCONJUGATES OF RNA INTERFERENCE AGENTS

 #2079
20190262384
2019-08-29

TGF-beta oligonucleotide for use in treatment of ophthalmic diseases

 #2080
20190256849
2019-08-22

Targeting ligands

 #2081
20190256848
2019-08-22

Antisense oligomers targeting HOXB-AS3 long non-coding RNA

 #2082
20190256845
2019-08-22

COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)

 #2083
20190256829
2019-08-22

Materials and methods for treatment of hemoglobinopathies

 #2084
20190249180
2019-08-15

Compositions and methods for correcting limb girdle muscular dystrophy type 2C using exon skipping

 #2085
20190249178
2019-08-15

Compositions and methods for treatment of cardiac diseases

 #2086
20190249177
2019-08-15

Modulation of huntingtin expression

 #2087
20190249173
2019-08-15

METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS

 #2088
20190247420
2019-08-15

Compounds and methods for reducing ATXN3 expression

 #2089
20190241911
2019-08-08

Engineered guide RNA and uses thereof

 #2090
20190241896
2019-08-08

Modulators of DNM2 expression

 #2091
20190241892
2019-08-08

MODULATION OF EXON RECOGNITION IN PRE-MRNA BY INTERFERING WITH THE SECONDARY RNA STRUCTURE

 #2092
20190233827
2019-08-01

Modulation of prekallikrein (PKK) expression

 #2093
20190233821
2019-08-01

RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)

 #2094
20190225970
2019-07-25

MODULATORS OF GROWTH HORMONE RECEPTOR

 #2095
20190225968
2019-07-25

SPHERICAL NUCLEIC ACID TLR9 AGONISTS

 #2096
20190225965
2019-07-25

Oligonucleotide compounds for targeting huntingtin mRNA

 #2097
20190225964
2019-07-25

MODULATION OF EXON RECOGNITION IN PRE-MRNA BY INTERFERING WITH THE SECONDARY RNA STRUCTURE

 #2098
20190224326
2019-07-25

Nucleic acid conjugates and uses thereof

 #2099
20190218557
2019-07-18

INHIBITION OF PCSK9 THROUGH RNAI

 #2100
20190218554
2019-07-18

Mixed tricyclo-DNA, 2′-modified RNA oligonucleotide compositions and uses thereof